Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,692 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study.
Nakajima K, Mizokami A, Matsuyama H, Ichikawa T, Kaneko G, Takahashi S, Shiina H, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A; PROSTAT-BSI Investigators. Nakajima K, et al. Among authors: sugiyama y. Int J Urol. 2021 Sep;28(9):955-963. doi: 10.1111/iju.14614. Epub 2021 Jun 19. Int J Urol. 2021. PMID: 34148264 Free PMC article.
Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index (PROSTAT-BSI) study.
Nakajima K, Kaneko G, Takahashi S, Matsuyama H, Shiina H, Ichikawa T, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A, Mizokami A; PROSTAT-BSI Investigators. Nakajima K, et al. Among authors: sugiyama y. Int J Urol. 2018 May;25(5):492-499. doi: 10.1111/iju.13556. Epub 2018 Apr 6. Int J Urol. 2018. PMID: 29633398
Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysis.
Kamijima T, Yaegashi H, Mizokami A, Nakajima K, Matsuyama H, Ichikawa T, Nishimoto K, Takahashi S, Shiina H, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A, Enokida H. Kamijima T, et al. Among authors: sugiyama y. Anticancer Res. 2022 Jun;42(6):3099-3108. doi: 10.21873/anticanres.15798. Anticancer Res. 2022. PMID: 35641302
Summary of the Clinical Practice Guidelines for Penile Cancer 2021 by the Japanese Urological Association.
Yamaguchi T, Sugiyama Y, Tanaka T, Kimura T, Yumura Y, Nakano M, Sugiyama T, Miura N, Goya M, Yamamoto A, Takahashi S, Miura Y, Tsuzuki T, Masumori N, Nishiyama H, Yao M, Koie T, Miyake H, Saika T, Saito S, Akimoto T, Tamada T, Ando Y, Takahashi S, Suzuki T, Hinotsu S, Kamba T. Yamaguchi T, et al. Among authors: sugiyama t, sugiyama y. Int J Urol. 2022 Aug;29(8):780-792. doi: 10.1111/iju.14924. Epub 2022 May 28. Int J Urol. 2022. PMID: 35643932 Review.
Predictive factors for the effectiveness of novel androgen receptor axis-targeted agents in patients with metastatic prostate cancer.
Koshiro N, Nakajima K, Oyama M, Kaneko G, Takahashi S, Matsuyama H, Shiina H, Ichikawa T, Horikoshi H, Hashine K, Sugiyama Y, Miyao T, Kamiyama M, Harada K, Ito A, Mizokami A; PROSTAT-BSI Investigators. Koshiro N, et al. Among authors: sugiyama y. Int J Urol. 2022 Dec;29(12):1477-1487. doi: 10.1111/iju.15022. Epub 2022 Sep 7. Int J Urol. 2022. PMID: 36070138
GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401.
Yokomizo A, Shiota M, Morokuma F, Eto M, Matsuyama H, Matsumoto H, Kamoto T, Terada N, Kawahara K, Enokida H, Tatarano S, Fujimoto N, Higasijima K, Sakai H, Hakariya T, Igawa T, Suekane S, Kamba T, Sugiyama Y, Kishimoto J, Naito S. Yokomizo A, et al. Among authors: sugiyama y. Int J Urol. 2024 Apr;31(4):362-369. doi: 10.1111/iju.15371. Epub 2023 Dec 26. Int J Urol. 2024. PMID: 38148124 Clinical Trial.
2,692 results